Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22632087 | 0.86 | CYP2D6 (0.76) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL6031499 | 0.85 | CYP2D6 (0.76) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL9387319 | 0.84 | CYP2D6 (0.74) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL17299899 | 0.82 | CYP2D6 (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL6229629 | 0.82 | DYRK1A (0.78) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL24025689 | 0.82 | CYP2D6 (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL18921190 | 0.82 | CYP2D6 (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL67779 | 0.82 | CYP2D6 (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL29443248 | 0.82 | CYP2D6 (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK | |
| SCHEMBL3194989 | 0.82 | KDM4E (0.72) | CYP2D6KDM4EALDH1A1HPGDLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023229884-A2 | 3'-BLOCKED NUCLEOTIDES, METHODS OF DEBLOCKING THE SAME, AND METHODS OF SYNTHESIZING POLYNUCLEOTIDES USING THE SAME | ILLUMINA, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-108368095-B | D-proline derivatives as SAP consumables | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-06-08 | — | — | CN | disclosed |
| US-10597385-B2 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-24 | — | — | US | disclosed |
| US-10328052-B2 | D-proline derivatives as SAP depleting agent | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-06-25 | — | — | US | disclosed |
| EP-3137457-B1 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| EP-3368532-A1 | D-PROLINE DERIVATIVES AS SAP DEPLETING AGENT | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-09-05 | — | — | EP | disclosed |
| US-20180099955-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
| US-9873686-B2 | Prodrug of 1,1′-(1,6-dioxo -1,6-hexanediyl)bis-D-proline | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-01-23 | — | — | US | disclosed |
| US-20170267665-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-09-21 | — | — | US | disclosed |
| US-9737505-B2 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-22 | — | — | US | disclosed |
| EP-3137457-A1 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-03-08 | — | — | EP | disclosed |
| US-20160081983-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | US | disclosed |
| US-20160075694-A1 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| WO-2015165833-A1 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-11-05 | — | — | WO | disclosed |
| EP-2139463-B1 | ANTI-INFECTIVE AGENTS | TECH UNIVERSITÄT CAROLO WILHELMINA ZU BRAUNSCHWEIG (DE) | 2014-08-20 | — | — | EP | disclosed |
| EP-1685150-B1 | NOVEL 17beta HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | SOLVAY PHARM GMBH (DE) | 2008-09-03 | — | — | EP | disclosed |
| EP-1075539-B1 | 7-ALKOXYCOUMARINS AS CYTOCHROME P450 SUBSTRATES | SMITHKLINE BEECHAM PLC (GB) | 2008-08-06 | — | — | EP | disclosed |
| US-6617124-B1 | Assay for testing for enzyme inhibitors which comprises contacting the enzyme and a compound of given formula; measuring inhibition of O-dealkylation of the compound by the enzyme | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-09 | — | — | US | disclosed |
| EP-1075539-A1 | 7-ALKOXYCOUMARINS AS CYTOCHROME P450 SUBSTRATES | SMITHKLINE BEECHAM PLC (GB) | 2001-02-14 | — | — | EP | disclosed |
| WO-1999058710-A1 | 7-ALKOXYCOUMARINS AS CYTOCHROME P450 SUBSTRATES | SMITHKLINE BEECHAM PLC (GB) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267665-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | APP, P4HA1, IAPP | CYP2D6 379/4885KDM4E 1909/4885ALDH1A1 433/4885 |
| US-20160075694-A1 | A PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | APP, P4HA1, FAP | CYP2D6 202/4885KDM4E 1956/4885ALDH1A1 235/4885 |
| US-10328052-B2 | D-proline derivatives as SAP depleting agent | APP, IAPP, PRAP1 | CYP2D6 3433/4885KDM4E 1699/4885ALDH1A1 2075/4885 |
| US-20180099955-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | APP, P4HA1, IAPP | CYP2D6 379/4885KDM4E 1909/4885ALDH1A1 433/4885 |
| US-10597385-B2 | Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline | APP, P4HA1, IAPP | CYP2D6 367/4885KDM4E 1905/4885ALDH1A1 433/4885 |
| US-20160081983-A1 | PRODRUG OF 1,1'-(1,6-DIOXO-1,6-HEXANEDIYL)BIS-D-PROLINE | APP, P4HA1, IAPP | CYP2D6 379/4885KDM4E 1909/4885ALDH1A1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.